G Caldarola
Overview
Explore the profile of G Caldarola including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Caldarola G, Pinto L, Acri M, Ala L, Bernardini N, Colonna L, et al.
Int J Dermatol
. 2025 Mar;
PMID: 40075139
No abstract available.
2.
Burlando M, Megna M, Caldarola G, Bernardini N, Giofre C, Gisondi P, et al.
Eur Rev Med Pharmacol Sci
. 2024 Oct;
28(18):4298-4301.
PMID: 39359201
Objective: The use of biologic agents, mainly tumor necrosis factor (TNF)-α and interleukin (IL)-17A inhibitors, was associated with cutaneous side effects, but the factors associated with eczematous reactions occurring during...
3.
Piraccini B, Pampaloni F, Cedirian S, Quadrelli F, Bruni F, Rapparini L, et al.
J Eur Acad Dermatol Venereol
. 2024 Sep;
PMID: 39247945
Background: Alopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows and eyelashes, for which treatments are limited. Baricitinib, an oral inhibitor of Janus kinases...
4.
Orsini D, Megna M, Assorgi C, Balato A, Balestri R, Bernardini N, et al.
J Dermatolog Treat
. 2024 Aug;
35(1):2393376.
PMID: 39164008
The aim of this multicenter observational study is to report data from real world on the use of bimekizumab in patients aged ≥ 65 years with moderate-to-severe plaque psoriasis. Elderly...
5.
Chiricozzi A, Ferrucci S, Di Nardo L, Gori N, Balato A, Ortoncelli M, et al.
Expert Opin Biol Ther
. 2023 Dec;
23(12):1307-1315.
PMID: 38108300
Background: Tralokinumab is a human monoclonal antibody targeting interleukin-13 that is approved for the treatment of moderate-severe atopic dermatitis. Studies analyzing the efficacy and safety of tralokinumab in a real-world...
6.
Quattrini L, Caldarola G, Falco G, Pinto L, Peris K
J Eur Acad Dermatol Venereol
. 2023 Jul;
37(12):e1432-e1434.
PMID: 37458532
No abstract available.
7.
Avallone G, Cavallo F, Astrua C, Caldarola G, Conforti C, De Simone C, et al.
J Eur Acad Dermatol Venereol
. 2022 Jun;
36(11):e876-e879.
PMID: 35771093
No abstract available.
8.
Quattrini L, Verardi L, Caldarola G, Peluso G, De Simone C, DAgostino M
J Eur Acad Dermatol Venereol
. 2021 Jul;
35(11):e727-e729.
PMID: 34236728
No abstract available.
9.
Galluzzo M, Caldarola G, De Simone C, Bernardini N, Moretta G, Pallotta S, et al.
Expert Opin Biol Ther
. 2021 Jun;
21(9):1299-1310.
PMID: 34114515
: Information is limited from real-life studies evaluating the efficacy and safety of brodalumab.: In this real-life study, we retrospectively examined a database of 90 patients with moderate-to-severe psoriasis treated...
10.
Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa J, et al.
Am J Clin Dermatol
. 2021 Mar;
22(4):567-579.
PMID: 33786754
Background: Drug survival analysis of biologic agents in psoriasis is of extreme importance, as it allows not only the evaluation of objective clinical outcomes (such as effectiveness and safety) but...